VTRS vs ALVO vs NTRB Stock Comparison

Viatris, Alvotech and NutriBand Prices as of Oct 28, 2026 Peers: Industry group
VTRS Viatris Inc
$18.77 +2.7% 1M +82.4% 1Y
Market cap
$21.56B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
2.56%
Generic Drugs Healthcare
7 wins
ALVO Alvotech
$4.94 -19.7% 1M -37.2% 1Y
Market cap
$1.54B
P/E
–
Revenue (TTM)
$105.94M
Div. yield
–
Generic Drugs Healthcare
1 win
NTRB NutriBand Inc.
$6.49 -21.1% 1M -16.4% 1Y
Market cap
$78.89M
P/E
–
Revenue (TTM)
$1.62M
Div. yield
–
Generic Drugs Healthcare
2 wins

Head to Head

10 decided of 12

Viatris leads on 7 of the 12 questions below (Viatris 7, NutriBand 2, Alvotech 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVTRSALVONTRBLeader
Larger companyMarket capitalisation $21.56B $1.54B $78.89M VTRS
Cheaper on earningsLower P/E, profitable companies only -53.2x -5.4x -11.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 7.2x — 3.9x NTRB
Faster revenue growthRevenue growth, trailing twelve months +4.4% -74.3% -37.3% VTRS
More profitableNet margin, trailing twelve months -2.8% -248.0% -430.4% VTRS
Better return on capitalReturn on invested capital -0.2% 4.4% — ALVO
Less leveragedLower net debt / EBITDA 4.6x 13.1x 0.5x NTRB
Higher dividend yieldTrailing dividend yield 2.56% — — –
Better 1-year returnPrice return, last 12 months +82.4% -37.2% -16.4% VTRS
Better 5-year returnAnnualised price return, 5 years +7.1%/yr -13.0%/yr +3.9%/yr VTRS
Less volatileAnnualised volatility, 1 year 32.3% 81.7% 79.8% VTRS
Higher overall scoreMean of the five percentile scores vs peers 66/100 48/100 50/100 VTRS

Percentile Scorecard

VTRSALVONTRB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVTRSALVONTRB
Valuation 93 #43 of 625 72 #173 of 625 55 #285 of 625
Growth 48 #312 of 602 35 #394 of 602 43 #345 of 602
Profitability 81 #103 of 549 68 #174 of 549 36 #354 of 549
Financial Health 22 #508 of 654 16 #553 of 654 68 #209 of 654
Shareholder Returns 86 #54 of 367 – –
Overall 66 48 50
  • VTRS ranked among 672 companies in Pharmaceuticals and Biotechnology
  • ALVO ranked among 672 companies in Pharmaceuticals and Biotechnology
  • NTRB ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVTRSALVONTRBSPY
1 month +2.7%-19.7%-21.1% +0.9%
3 months +5.3%+39.9%+125.3% +5.9%
6 months +25.4%+49.7%+71.2% +8.5%
Year to date +50.8%-3.7%+43.0% +13.3%
1 year +82.4%-37.2%-16.4% +12.4%
3 years +114.0%-45.0%+207.6% +88.1%
3 years, per year +28.9%-18.1%+45.5% +23.5%
5 years +40.6%-50.1%+20.9% +68.2%
5 years, per year +7.1%-13.0%+3.9% +11.0%
10 years -49.5%—— +263.4%
10 years, per year -6.6%—— +13.8%

Risk

MeasureVTRSALVONTRBSPY
Volatility, 1Y 32.3%81.7%79.8% 12.7%
Downside volatility, 1Y 29.7%86.3%75.3% 12.7%
Beta vs S&P 500, 1Y 0.700.751.03 1.00
Return / volatility, 1Y 2.55-0.46-0.20 0.98
Max drawdown, 5Y -52.9%-82.6%-77.7% -25.4%
From 52-week high 0.0%-37.5%-27.8% -0.9%
52-week high $18.77$7.90$8.99 $779.14
52-week low $10.11$3.00$2.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVTRSALVONTRB
P/E now vs peer median -53.2xmedian 17.4x -5.4xmedian 17.4x -11.3xmedian 17.4x
P/S now vs peer median 1.5xmedian 9.1x 14.5xmedian 9.1x 48.8xmedian 9.1x
EV/EBITDA now vs peer median 12.5xmedian 17.1x 30.4xmedian 17.1x -11.0xmedian 17.1x
P/FCF now vs peer median 11.0xmedian 19.0x -5.9xmedian 19.0x -21.7xmedian 19.0x
P/B now vs peer median 1.5xmedian 2.2x -8.0xmedian 2.2x 14.8xmedian 2.2x
PEG now vs peer median 1.74median 0.34 -0.22median 0.34 -13.80median 0.34

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVTRSALVONTRB
Revenue $14.74B $105.94M $1.62M
Gross profit $5.13B $7.66M $536.12K
Operating income -$87.30M $47.54M -$7.05M
Net income -$410.70M -$179.60M -$6.96M
Free cash flow $1.95B -$261.39M -$3.63M
R&D $1.02B $46.37M $1.21M
EPS (diluted) $-0.35 $-0.90 $-0.57
Cash & equivalents $886.50M $142.80M $3.42M
Total debt $13.35B $1.31B $647.66K
Shares (diluted) 1.16B 291.34M 12.16M
Enterprise value $16.57B $1.11B $61.58M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVTRSALVONTRB
P/E -53.2x -5.4x -11.3x
P/FCF 11.0x -5.9x -21.7x
P/Operating cash flow 9.2x -7.8x -21.7x
P/S 1.5x 14.5x 48.8x
P/B 1.5x -8.0x 14.8x
P/Tangible book 36.9x -4.6x 15.3x
EV/EBITDA 12.5x 30.4x -11.0x
EV/EBIT -389.7x 56.9x -10.7x
EV/Revenue 2.3x 25.5x 46.7x
EV/FCF 17.4x -10.3x -20.8x
EV/Operating cash flow 14.6x -13.6x -20.8x
PEG (3Y EPS CAGR) 1.74 -0.22 -13.80

Growth

14 metrics
MetricVTRSALVONTRB
Revenue growth (1Y) 4.4% -74.3% -37.3%
Revenue CAGR (3Y) -1.9% 104.2% -10.8%
Gross profit growth (1Y) -0.7% -95.0% -39.5%
Gross profit CAGR (3Y) -6.0% 27.6% -16.5%
Operating income growth (1Y) 96.6% -13.3% 32.3%
Operating income CAGR (3Y) -27.6% 28.9% -15.3%
Net income growth (1Y) 88.2% -383.6% 32.2%
Net income CAGR (3Y) -30.5% 24.4% -14.8%
EPS growth (1Y) 88.1% -481.6% 80.0%
EPS CAGR (3Y) -30.6% 24.6% 0.8%
Operating cash flow growth (1Y) 12.9% -367.1% 25.9%
Operating cash flow CAGR (3Y) -3.0% 12.8% -5.7%
Free cash flow growth (1Y) 11.6% -113.0% 26.6%
Free cash flow CAGR (3Y) -3.6% 8.6% -5.5%

Profitability

14 metrics
MetricVTRSALVONTRB
Gross margin 34.8% 7.2% 33.1%
EBITDA margin 18.4% 83.9% -426.5%
Operating margin -0.6% 44.9% -435.6%
Pretax margin -4.5% -62.1% -430.4%
Net margin -2.8% -248.0% -430.4%
FCF margin 13.3% -246.7% -224.5%
Operating cash flow margin 15.8% -187.6% -224.5%
Return on equity -2.8% – -123.0%
Return on assets -1.1% -17.5% -105.6%
Return on invested capital -0.2% 4.4% –
Return on capital employed -0.3% 4.1% -123.9%
Asset turnover 0.4x 0.1x 0.2x
Cash conversion (OCF / net income) -5.7x 1.1x 0.5x
Stock comp / revenue 1.2% 8.7% 204.1%

Financial Health

11 metrics
MetricVTRSALVONTRB
Debt / assets 38.1% 82.3% 2.4%
Debt / equity 0.9x -6.8x 0.0x
Net debt / EBITDA 4.6x 13.1x 0.5x
Debt / FCF 6.8x -5.0x 0.0x
Liabilities / assets 59.3% 112.1% 15.3%
Equity / assets 40.7% -12.1% 84.7%
Interest coverage -0.2x 0.8x -339.3x
Current ratio 1.6x 1.6x 4.2x
Quick ratio 0.7x 1.1x 3.8x
Cash ratio 0.1x 0.4x 3.8x
Altman Z-score 1.15 -1.34 35.34

Shareholder Returns

7 metrics
MetricVTRSALVONTRB
Dividend yield 2.6% – –
Net buyback yield 1.4% – –
Shareholder yield 4.0% – –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVTRSALVONTRB
Forward P/E 7.2xFY2026 – 3.9xFY2026
EPS, next fiscal year $2.62FY2026 $-0.01FY2026 $1.65FY2026
EPS growth, next FY +11.5%FY2026 – –
EPS growth, the year after -1.5% – +112.1%
Revenue, next fiscal year $15.31BFY2026 $556.32MFY2026 $90.32MFY2026
Revenue growth, next FY +7.0%FY2026 -6.2%FY2026 +4,334.5%FY2026
Revenue growth, the year after -4.8% +23.2% +109.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVTRSALVONTRB
Held by institutions 89.9% 14.7% –
Institutions holding 1,029 72 –
Change in shares held, QoQ +5.6% +152.4% –
Institutions buying 487 44 –
Institutions selling 318 17 –
Buyers to sellers 1.53 2.59 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VTRSALVONTRB
VTRS 1.00 0.05 0.06
ALVO 0.05 1.00 0.18
NTRB 0.06 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VTRS, ALVO and NTRB?

Viatris (VTRS) is the largest by market capitalisation: Viatris (VTRS) $21.56B, Alvotech (ALVO) $1.54B, NutriBand (NTRB) $78.89M.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Viatris (VTRS) +4.4%, Alvotech (ALVO) -74.3%, NutriBand (NTRB) -37.3%.

Which company is more profitable?

Viatris (VTRS) has the highest net margin (Viatris (VTRS) -2.8%, Alvotech (ALVO) -248.0%, NutriBand (NTRB) -430.4%). On return on invested capital, Alvotech (ALVO) leads (Viatris (VTRS) -0.2%, Alvotech (ALVO) 4.4%).

Which stock has performed better?

Over the past year Viatris (VTRS) returned the most: Viatris (VTRS) +82.4%, Alvotech (ALVO) -37.2%, NutriBand (NTRB) -16.4%. Over five years, Viatris (VTRS) compounded fastest (Viatris (VTRS) +7.1%/yr, Alvotech (ALVO) -13.0%/yr, NutriBand (NTRB) +3.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Viatris (VTRS) 2.56%. Alvotech (ALVO) and NutriBand (NTRB) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Viatris (VTRS) has been the steadiest (Viatris (VTRS) 32.3%, Alvotech (ALVO) 81.7%, NutriBand (NTRB) 79.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, VTRS, ALVO and NTRB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Viatris (VTRS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.